Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydrocortisone - Diurnal

Next Previous
Drug Profile

Hydrocortisone - Diurnal

Alternative Names: Alkindi; ALKINDI SPRINKLE; Chronocort; DNL-0200; EFMODY; Efmody; Hydrocortisone extended release - Diurnal; Infacort; Modified-release hydrocortisone

Latest Information Update: 17 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Diurnal
  • Developer Diurnal; EffRx; Emerge Health; Eton Pharmaceuticals; Medison Pharma
  • Class Alcohols; Anti-inflammatories; Antiallergics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital adrenal hyperplasia; Adrenal insufficiency
  • New Molecular Entity No

Highest Development Phases

  • Marketed Adrenal insufficiency; Congenital adrenal hyperplasia

Most Recent Events

  • 17 Mar 2025 Launched for Congenital adrenal hyperplasia in Switzerland (PO), before March 2025 (EffRx pipeline, March 2025)
  • 01 Jun 2024 Interim efficacy data from a phase II CHAMPION trial in Adrenal insufficiency presented at the 106th Annual Meeting of the Endocrine Society (ENDO-2024)
  • 14 May 2024 Efficacy data from phase III extension study for Congenital adrenal hyperplasia released by Neurocrine Biosciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top